Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Redrow CEO to step down as Barratt integration nears completion

(Sharecast News) - Housebuilder Barratt Redrow has announced that the former head of Redrow is to step down in June as the operational integration of the two companies nears completion. Matthew Pratt, who has worked for Redrow for 22 years, including five years as chief executive prior to last year's £2.5bn merger, will leave the board on 30 June, but remain available until the end of the year as needed.

David Thomas, the CEO of the enlarged group who was the head of standalone Barratt from 2015, said Pratt played a "key role in the smooth and effective integration of Barratt and Redrow".

"I would like to thank him for his valuable contribution to the combined business," Thomas said.

In a statement, Pratt said: "As we approach the final stages of operational integration, I am immensely proud to have contributed to the coming together of these two exceptional businesses. I wish Barratt Redrow every success as it embarks on this exciting new chapter."

In other news, with current chief operating officer and deputy CEO Steven Boyes set to retire in September, as previously announced, Barratt Redrow has appointed Mike Roberts as its new COO. Roberts, who is currently regional managing director for the north, will become COO on 6 September.

Barratt Redrow shares were up 1.2% at 420.9p by 1304 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.